Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus NALIRIFOX or gemcitabine-cisplatin as first-line therapy for advanced biliary tract cancer
ChiCTR2600116738Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adebrelimab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate (ORR), Incidence of adverse events (AE) and 5 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600116738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116738.